Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,002 DKK | -1.91% | -1.14% | -7.10% |
05-15 | Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation' | MT |
05-15 | Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.10% | 19.19B | |
+8.63% | 115B | |
+13.17% | 107B | |
-12.76% | 22.31B | |
-3.99% | 21.6B | |
-7.19% | 18.23B | |
-39.93% | 17.62B | |
+6.67% | 14.26B | |
+33.90% | 12.37B | |
-28.60% | 8.28B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Morgan Stanley Adjusts Price Target on Genmab to $32 From $33, Maintains Underweight Rating